AIDS/HIV treatment

Unique Cell Treatment Clinic pays great attention to AIDS treatment. For doctors of the clinic struggle with this "Plague of the twentieth century" is a matter of honor. The first investigations and trials in this field Professor Alexander Smikodub began in 1992, and already in 1998 he received a priority for the invention of a method of controlling this disease using suspensions with fetal stem cells:

Patent for an invention № 6184033В1, USA

Inventor: Alexandr Smikodub

“Medicinal Preparation Based on Fetal Suspensions Having Immune Substituting Effect for Patients with Acquired Immune Deficiency Syndrome (HIV-infection)”

Priority date of invention: 18th of September 1998

Date of Patent: 6th of February 2001

Acquired immune deficiency syndrome isa serious infectious disease caused by the human immunodeficiency virus (HIV), for today it remains a major medical and social problem worldwide. The virus attacks the immune system, resulting in the "suppression" of its functioning and decrease in the body's ability to resist - develop secondary infectious and neoplastic processes. AIDS is already the terminal end-stage of HIV transmission, when appear clinical manifestations of the disease. As it is known, the main ways of infection are sexual, transfusion (through blood) and from mother to child (during pregnancy, delivery or breastfeeding). Since the majority of HIV-infected people have no symptoms, and the latent period can last up to ten years, it contributes to the wide spread of the virus through sexual contacts. First clinical signs caused by a decrease in the protective properties of the body from infection (preAIDS) may be: swollen lymph nodes, unexplained fever associated with a sharp decline in physical activity, sweating, especially at night, weight loss. In fact, AIDS as a manifestation of failure of the immune system, can be determined either by development of severe infections or by development of tumors. About 50% of patients die from pneumonia caused by atypical pathogens resistant to existing therapies. In most patients is also observed damage to the central nervous system (meningitis, encephalitis, brain tumors, dementia), lesions of the skin and mucous membranes in form of Kaposi's sarcoma, of fungal (candidiasis) or viral (from the family of herpes viruses) origin.

There are no specific methods of  treatment for AIDS developed, for the treatment is usually used a combination of antiviral drugs (Highly Active Anti-Retroviral Therapy, HAART) and immunostimulatory agents, and the treatment of opportunistic infections and Kaposi's sarcoma is performed. Despite the tremendous efforts, to which resort the physicians all over the world, patients with expanded AIDS clinical picture rarely live more than two years. Antiretroviral drugs that are currently in use, do not kill the virus completely, but only prevent the spread and reproduction of HIV in the cells of the human immune system, at that having a lot of side effects. Timely started antiretroviral treatment, when indicated (lowered immunity and/or high viral load), in hundred times reduces the risk of AIDS development. Upon the termination of their intake, disease continues to develop. Considering the fact that many patients for any reason interrupt treatment, as well as constant variability of HIV leading to drug resistance, there is a need for alternative methods of therapy.

Unlike methods of healing based on the inhibition of virus development, the UCTC clinic has developed and successfully uses treatment schemes of HIV infection and acquired immune deficiency syndrome based on the use of fetal stem cells, which are aimed on raising the body's immune barrier to normal values. In this case, the disease simply does not occur. Fetal stem cells have strong complex immunocorrecting properties that allow using them effectively at any stage of the disease and in all forms of clinical manifestations of AIDS. Healing with drugs on the basis of fetal stem cells by method of Prof. Smikodub allows to restore and maintain the parameters of immunity in HIV infection, thereby preventing the development of the disease progression, especially when there is no direct evidence for antiretroviral therapy. Our treatment significantly improves the clinical course of the disease and is effective for the prevention of secondary complications of infectious and oncological nature. In the complex use with highly active antiretroviral therapy, the annual planned repeated courses of stem cell treatment by method of Prof. Smikodub facilitate its tolerability, enhance the quality of life of the patient, increasing its duration. Modern antiviral therapy effectively prevents the growth and spread of HIV, however, if there is already severe depression of the immune system, the patient's prognosis worsens significantly. Positive immunocorrecting effects and clinical remission of the disease after stem cell treatment in the UCT Clinic lasts from one to two years. Our therapy as a stem cell treatment for HIV, in respect of efficiency and availability is a viable alternative for today, especially if it is impossible further to perform the traditional methods due to their poor tolerability.